Research published in late 2024 in the journal JAMA Pediatrics found nirsevimab was more than 90 percent effective at preventing hospitalization for RSV, and 89 percent effective at preventing all ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback